Evotec (NASDAQ:EVO) Shares Gap Up to $7.07

Shares of Evotec SE (NASDAQ:EVO) gapped up prior to trading on Monday . The stock had previously closed at $7.07, but opened at $7.36. Evotec shares last traded at $7.35, with a volume of 15,314 shares changing hands.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th.

Evotec Stock Up 3.9 %

The firm’s fifty day moving average is $7.37 and its 200 day moving average is $8.71.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quadrant Capital Group LLC bought a new position in shares of Evotec during the 4th quarter worth about $25,000. Optiver Holding B.V. raised its position in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC bought a new stake in Evotec during the fourth quarter worth about $53,931,000. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.